tbuckley/cabot-search huggingface dataset:
Approach to offering remote support to mesothelioma patients: The Mesothelioma Survivor Project.
Authors: Gleneara Elizabeth Bates, Toby Bressler, Anisah Khurshid Hashmi, Mary Hesdorffer, Robert N. Taub
Journal: Journal of Clinical Oncology (2016)

82 Background: From the moment of diagnosis, malignant mesothelioma (MM), decreases health-related quality-of-life (QOL) in patients and their caregivers. In addition to symptoms of disease, aggressive treatments such as surgery, radiation, and chemotherapy can cause extreme side effects – specifically, chemotherapy is associated with chronic fatigue, unremitting nausea, vomiting, and systemic pain. These side effects of treatments can be burdensome enough to lead to noncompliance or outright refusal of continuation of care.[1] Data from 13 frequently cited QOL studies focus on chest pain and shortness of breath as the two chief symptoms of pleural mesothelioma. The largest QOL study to date enrolled 495 patients, evaluated MM using the LCSS (lung cancer symptom scale). Investigators reported MM’s most common symptoms as: fatigue (94%), dyspnea (89%), loss of appetite (86%), chest pain (85%), cough (75%), and hemoptysis (24%). In addition, mesothelioma has a number of emotional consequences. A study by the British Lung Foundation (BLF) reported significant impairment of emotional function and/or emotional state in patients with mesothelioma and their family members.[2] Methods: The platform for the support group was remote, consisting of both online and telephone domains. Participants would utilize both online and phone systems during sessions, held once a week for a total of 6 weeks. Sessions were guided and kept closed, available only to those affected by mesothelioma. Participants completed surveys after each support group. Session summaries and follow-up information were provided online after support meetings. Results: Using a 0-5 Likert Scale, consistent attendees reported support groups as very helpful (4). Irregular attendees had mixed feelings ranging from extremely helpful (5) to neutral (3). 80% of attendees participated in support groups prior to ours. Conclusions: Active participation in a guided and closed support group allowed participants to share their experiences and concerns about their diagnoses, comfortably – supporting transition beyond active-treatment. The online portion of the platform was helpful in assuaging common negative concerns.
Ongoing outbreaks of hepatitis A among men who have sex with men (MSM), Berlin, November 2016 to January 2017 – linked to other German cities and European countries
Authors: Dirk Werber, Kai Michaelis, Marius Hausner, Dagmar Sissolak, Jürgen Wenzel, Julia Bitzegeio, Anne Belting, Daniel Sagebiel, Mirko Faber
Journal: Eurosurveillance (2017)

Since 14 November 2016, 38 cases of hepatitis A have been notified in Berlin; of these, 37 were male and 30 reported to have sex with men (MSM). Median age of MSM cases is 31 years (range: 24–52 years). Phylogenetic analysis revealed three distinct sequences, linking cases in Berlin to those in other German cities and to clusters recognised in other European countries in 2016.
46P Identification of novel biomarkers distinguishing pancreatic head cancer from distal cholangiocarcinoma discovered by proteomics analysis
Authors: T. Takenami, S. Maeda, H. Karasawa, Y. Mochizuki, T. Aizawa, S. Jun, H. Musha, T. Morikawa, K. Nakagawa, H. Hayashi, F. Motoi, T. Naitoh, M. Unno
Journal: Annals of Oncology (2016)
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study
Authors: A. Musolino, A. Sikokis, D. Boggiani, A. Rimanti, B. Pellegrino, E.M. Silini, N. Campanini, E. Barbieri, L. Cortesi, M. Panebianco, R. Porzio, A. Frassoldati, P. Sgargi, F. Falcini, M. Michiara
Journal: Annals of Oncology (2016)
Blockade of Highly Expressed CD55 Related to Tumor Bulkiness by RNA Interference Overcomes Resistance to CDC with Rituximab.
Authors: Yasuhito Terui, Takuma Sakurai, Yuko Mishima, Yuji Mishima, Masahiro Yokoyama, Shunji Takahashi, Yoshinori Itoh, Kiyohiko Hatake
Journal: Blood (2004)
MiR-141 to confer the docetaxel chemoresistance of breast cancer cells via regulating EIF4E expression.
Authors: Lu Yue, Ya-sai Yao, Wen-sheng Qiu, Qian Zhang, Li-kun Zhuang, Fei Zhou, Li-bin Sun, Ru-yong Yao
Journal: Journal of Clinical Oncology (2015)

e12007 Background: Resistance to docetaxel, a chemotherapy drug for breast cancer treatment, occurs in about 50% of patients, and the underlying molecular mechanisms of drug resistance are not fully understood. Gene regulation through miR-141 has been shown to play an important role in cancer drug resistance. This study investigated the role of miR-141 expression in breast cancer cells of acquired docetaxel resistance. Methods: We detected miR-141 expression in docetaxel-resistant (MCF-7/DTX, MDA-MB-231/DTX) and docetaxel-sensitive (MCF-7, MDA-MB-231) breast cancer cells and then focused on its roles in regulation of docetaxel chemoresistance. We also identified EIF4E as a novel target of miR-141 by luciferase assay. Results: Inhibition of miR-141 enhanced response to docetaxel in MCF-7/DTX and MDA-MB-231/DTX cells, respectively; whereas overexpression of miR-141 confered the resistance in MCF-7, MDA-MB-231 cells, respectively. By directly targeting EIF4E mRNA, miR-141 acts on genes that are necessary for drug induced apoptosis rendering cells drug resistant. Modulation of miR-141 expression was correlated with EIF4E expression changes and EIF4E was identified as a novel target of miR-141. Conclusions: This study is the first to show increased expression of miR-141 in an acquired model of docetaxel resistance in breast cancer. This serves as a mechanism of acquired docetaxel resistance in breast cancer cells, possibly through direct interactions with EIF4E, therefore presenting a potential therapeutic target for the treatment of docetaxel resistant breast cancer.
Medication therapy management (MTM) in a multidisciplinary supportive oncology clinic.
Authors: Robert Mancini, Kathleen Clifford, Michele Brown, Lori Watts, Dan Sayam Zuckerman, Rhone Levin, Valerie Robenstein
Journal: Journal of Clinical Oncology (2012)

30 Background: Patients with advanced cancer experience significant symptom burden and psychosocial distress from the onset of their diagnosis and throughout treatment shifting the paradigm of supportive care. In addition, most cancer patients have multiple co-morbidities and are at high risk of poly-pharmacy. One in three ambulatory cancer patients are at risk of drug-drug interactions. Methods: In June 2010, a multidisciplinary supportive oncology clinic, modeled after the Massachusetts General Hospital article by Temel et al., was started and staffed by a pharmacist, a nurse, a social worker and a dietitian and lead by a nurse practitioner. A chart audit was conducted for all patients seen in the clinic between June 2010 and March 2012. Pharmacy assessment entries were evaluated for diagnosis, medication issues and total time spent with patients. Duplicate therapy was defined as an unnecessary duplication in therapy for a single symptom and/or two medications in the same class. Drug-Interactions were assessed utilizing Micromedex 2.0 Drug-Interaction Checker and Lexicomp Lexi-Interact Online drug-interaction analysis program. All major kinetic interactions were recorded and pharmacodynamic interactions were recorded if they required intervention. Results: From June 2010 to May 2012, 153 patients were seen in the clinic. The most common diagnoses were pancreatic, lung, breast and head and neck. Use of a standardized pharmacy assessment identified duplicate therapies in 45.1% of patients, drug-drug interactions in 35.3%, side-effects in 83%, lack of efficacy in 88.9% and untreated conditions 68.6%. The pharmacists spent an average of 44.1 minutes (range 15-90 min) with patients. Conclusions: Pharmacist-initiated MTM identifies a higher rate of poly-pharmacy, drug-drug interactions and side effects than found in literature. Identification allows for referral to other disciplines within the clinic for work-up. Gastrointestinal related issues were referred to a dietitian, psychosocial issues including adherence issues to a social worker and medication related issues to the nurse practitioner for follow-up. Initial identification of these issues has allowed for more long-term follow-up in these patients.
Abstract 155: Cardiac Function And Calcium Handling in Obesity-Resistant rats
Authors: Andre Leopoldo, Felipe de Sá, Wagner Estevam, Bruno Jacobsen, Artur Ferron, Márcia da Cunha, Edson Castardeli, Dijon Campos, Antonio Cicogna, Ana Paula Lima Leopoldo
Journal: Circulation Research (2014)

Experimental studies have demonstrated that obesity induced by different types of high-fat and/or high-energy diets also lead to myocardial dysfunction. Nevertheless, few studies have evaluated the myocardial function in obesity-resistant rats. Moreover, the mechanisms underlying the participation of calcium (Ca 2+ ) handling on cardiac function in this model remain unknown. The aim of this study was to investigate in rodent model of obesity-resistant. In addition, as obesity-resistant group is fed a high-fat diet but did not become obese, this study tested whether obesity-resistant model develops cardiac abnormalities and impairment of calcium handling as obesity-prone. Male 30-day-old Wistar rats were fed standard (C) and alternately four palatable unsaturated high-fat diets (Ob) for 15 weeks. After experimental protocol, Ob rats consuming the unsaturated high-fat diets were ranked based on adiposity index. Rats on the unsaturated high-fat diets exhibiting the greatest adiposity index were referred to as OP, whereas those exhibiting the lowest adiposity index were referred to as OR. Obesity was determined by adiposity index and comorbidities were evaluated. Myocardial function was evaluated in isolated left ventricle papillary muscles under basal conditions and after inotropic and lusitropic maneuvers. After 15 weeks, final body weight, total body fat, adiposity index, triglycerides levels and heart weight were significantly greater in OP rats than C and OR rats, however, there was no change in systolic blood pressure between groups. The C, OP and OR muscles developed similar baseline data, but myocardial responsiveness to post-rest contraction stimulus was compromised in OP rats. In conclusion, obesity-resistant model by unsaturated high-fat diet, after 15 weeks, does not display nutritional and metabolic characteristics of obesity-prone. Furthermore, obesity-resistant does not promote cardiac abnormalities and impairment of calcium handling visualized in obesity-prone.
Is the ANS linked to mathematics performance?
Authors: Matthew Inglis, Sophie Batchelor, Camilla Gilmore, Derrick G. Watson
Journal: Behavioral and Brain Sciences (2017)

Abstract Leibovich et al. argue persuasively that researchers should not assume that approximate number system (ANS) tasks harness an innate sense of number. However, some studies have reported a causal link between ANS tasks and mathematics performance, implicating the ANS in the development of numerical skills. Here we report a p -curve analysis, which indicates that these experimental studies do not contain evidential value.
Detection of the V617F Mutation of JAK2 Using a Novel Fully Automated SNP Super-Rapid Detector.
Authors: Ruriko Tanaka, Junya Kuroda, Eishi Ashihara, Takayuki Ishikawa, Tomohiko Taki, Mitsuharu Hirai, Satoshi Majima, Masafumi Taniwaki, Taira Maekawa, Shinya Kimura
Journal: Blood (2007)
Oral metronomic Vinorelbine (OMV) in elderly pts with advanced NSCLC: pharmacokinetics and clinical outcome
Authors: F. Pasini, C. Barile, D. Caruso, Y. Modena, A. Fraccon, E. Pezzolo, F. La Russa, D. Menon, G. Crepaldi, R. Spezzano, A. Bononi, G. Corona, S. Ortolani, R. Padrini, M. Gusella
Journal: Annals of Oncology (2016)
P08.63 Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients with recurrent glioblastoma
Authors: A. F. Hottinger, M. Sanson, E. Moyal, J. Delord, K. Rezai, A. Leung, S. Perez, M. Bekradda, N. Lachaux, O. Chinot
Journal: Neuro-Oncology (2016)
Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study
Authors: Devendra K Hiwase, Peter Tan, James D'Rozario, John Taper, Anthony Richard Powell, Ian Irving, Matthew P.F. Wright, Susan Branford, David T. Yeung, Luke Anderson, Othon L Gervasio, Timothy P. Hughes
Journal: Blood (2016)
251P Association of Epstein-Barr virus with prognosis of patients with esophageal squamous cell carcinoma: A retrospective cohort study
Authors: S. Shahidsales, A. Moradi, F. Ghasemi, K. Anvari, S. Ahmadi-Simab, M.T. Boroushaki, A. Avan
Journal: Annals of Oncology (2016)
Engraftment Syndrome after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Graft-Versus-Host Disease Prophylaxis and T Cell Dose.
Authors: Robert M. Dean, Kyle M. Donley, Juan Gea-Banacloche, Seth M. Steinberg, Jeanne Odom, Michael Krumlauf, Kathleen Castro, Tracey Chinn, Daniel H. Fowler, Ronald E. Gress, Michael R. Bishop
Journal: Blood (2004)
A Test in Context: Lipoprotein(a)
Authors: Sotirios Tsimikas
Journal: Journal of the American College of Cardiology (2017)

Evidence that elevated lipoprotein(a) (Lp[a]) levels contribute to cardiovascular disease (CVD) and calcific aortic valve stenosis (CAVS) is substantial. Development of isoform-independent assays, in concert with genetic, epidemiological, translational, and pathophysiological insights, have established Lp(a) as an independent, genetic, and likely causal risk factor for CVD and CAVS. These observations are consistent across a broad spectrum of patients, risk factors, and concomitant therapies, including patients with low-density lipoprotein cholesterol <70 mg/dl. Statins tend to increase Lp(a) levels, possibly contributing to the “residual risk” noted in outcomes trials and at the bedside. Recently approved proprotein convertase subtilisin/kexin-type 9 inhibitors and mipomersen lower Lp(a) 20% to 30%, and emerging RNA-targeted therapies lower Lp(a) >80%. These approaches will allow testing of the “Lp(a) hypothesis” in clinical trials. This review summarizes the current landscape of Lp(a), discusses controversies, and reviews emerging therapies to reduce plasma Lp(a) levels to decrease risk of CVD and CAVS.
Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
Authors: Malcolm J. Moore, Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey R. Infante, Jeremy K. Hon, Mikhail Yu Biakhov, Sunil R. Hingorani, Vinod Ganju, Colin D. Weekes, Werner Scheithauer, Ramesh K. Ramanathan, Josep Tabernero, David Goldstein, Xinyu Wei, Alfredo Romano
Journal: Journal of Clinical Oncology (2013)

4059^ Background: In MPACT, pts who received nab-P + G vs G had improved overall survival (OS; median 8.5 vs 6.7 mo; HR 0.72; p= 0.000015). Here we assessed potential PFs of OS. Methods: 861 pts with MPC were randomized 1:1, stratified by region, presence of liver metastases, and Karnofsky performance status (KPS), to nab-P + G or G. OS was described in subgroups. A step-wise multivariate analysis (with significance level for entry of 0.20 and for stay of 0.10) was performed to evaluate the treatment effect and identify possible predictors of OS. Results: Pts with poorer PFs had a shorter median OS, consistent with the literature, and OS consistently favored nab-P + G in pts with these PFs (Table). Region of Eastern Europe, age ≥ 65 years, poorer KPS, presence of liver metastases, and number of metastatic sites all predicted OS (increased risk of death). The treatment effect remained significant (HR 0.72; 95% CI, 0.605 - 0.849; p &lt; 0.0001, Cox proportional hazards [CPH] model). In another multivariate analysis in which baseline CA19-9 was added to the final model described above, the treatment effect HR was 0.67 (95% CI, 0.573 - 0.794; p &lt; 0.0001, CPH model). Baseline CA19-9, a predictor of OS by univariate analysis, was not predictive after correction for the above factors. Conclusions: In MPACT, the most important predictors of OS were KPS, age, presence of liver metastases, number of metastatic sites, and region. After correcting for these factors, assignment to nab-P + G was an independent significant predictor of improved survival. Clinical trial information: NCT00844649. [Table: see text]
Ethnic disparities in adherence to breast cancer survivorship care.
Authors: Pragati Gole, Jun Ying, Richard L. Theriault, Amal Melhem-Bertrandt, Stacy L. Moulder, Welela Tereffe, Tunghi May Pini, Abenaa M. Brewster
Journal: Journal of Clinical Oncology (2013)

122 Background: Two major components of breast cancer survivorship care include surveillance with mammograms and clinic visits after completion of definitive treatment. Identifying disparities in adherence to survivorship care is critical for improving the care delivery and outcomes of patients. Methods: We evaluated adherence to survivorship care among 4,212 racially/ethnically diverse Texan residents who underwent surgery for stage I-III breast cancer at the MD Anderson Cancer Center between January, 1997 and December, 2006 and completed one year of survivorship care. We used generalized estimating equations (GEE) method to evaluate race/ethnicity differences in missed mammograms and clinic visits up to 4 years of survivorship care. Results: The mean age of the cohort was 53 years (range 22-91); 72% white, 11% black, 11% Hispanic and 5% other race/ethnicity. Over four years, 36% of patients missed an annual mammogram and 21% of patients did not have a minimum of 1 clinic visit per year. For the entire study cohort, the trend of missed annual mammograms per year of survivorship care follow-up was 6% (year 1), 17% (year 2), 19% (year 3) and 22% (year 4) (p-trend &lt;0.0001). In multivariable GEE model adjusted for survivorship year, age, stage, chemotherapy, endocrine therapy, radiation therapy and county of residence, Hispanic (OR 1.48 95% CI 1.22-1.80) and black (OR 1.41, 95% CI 1.15-1.72) patients were more likely be nonadherent with annual mammograms compared to white patients. Hispanic (OR 1.58, 95% CI 1.25-2.00) and black (OR 1.45, 95% CI 1.14-1.84) patients were also more likely to be nonadherent with clinic visits compared to white patients. There was a significant interaction between ethnicity and non-receipt of adjuvant endocrine therapy on clinic visit nonadherence (p-interaction=0.04) and annual mammogram nonadherence (p-interaction=0.001) among Hispanic compared to white patients. Conclusions: Drop out of breast cancer survivorship care increases over time and black and Hispanic women are more likely to be nonadherent. Better characterization of the reasons for nonadherence is needed to design interventions to improve retention in breast cancer survivorship care, especially for patients not receiving adjuvant endocrine therapy.
CD4+/bcl-6+ Peripheral T-Cell Lymphoma with Follicular Involvement: A Distinct Type of Nodal Peripheral T-Cell Lymphoma with Multiple T-Cell Clones.
Authors: Ida Munster-Ikonomou, Anne Tierens, Gunhild Troen, Hege Aamodt, Sverre Heim, Grete Lauritzsen, Jan Delabie
Journal: Blood (2004)
CNS Involvement in Childhood and Adolescence Non-Hodgkin Lymphoma: Prevalence and Patient’s Outcome Differ According to the Subtype.
Authors: Janina Salzburg, Birgit Burkhardt, Olga Wachowski, Martin Zimmermann, Reza Parwaresch, Wolf-Dieter Ludwig, Georg Mann, Felix Niggli, Hansjörg Riehm, Martin Schrappe, Alfred Reiter
Journal: Blood (2005)
IMST-13. DEXAMETHASONE ENHANCES CTLA-4 EXPRESSION DURING T CELL ACTIVATION
Authors: Amber Giles, Caitlin Reid, Marsha-Kay Hutchinson, Vinh Au, Heather Sonnemann, Deric Park, Mark Gilbert
Journal: Neuro-Oncology (2016)

Checkpoint inhibitor blockade, designed to activate anti-tumor immune cells, is gaining enthusiasm as a potential treatment modality for patients with brain tumors. However, adjuvant therapies aimed at killing tumor (i.e. chemotherapy) or reducing tumor-related edema (i.e. corticosteroids) are often cytotoxic to lymphocytes. Dexamethasone, the most commonly used corticosteroid, can induce immune suppression, although the mechanism remains unclear. We tested the effects of increasing concentrations of dexamethasone on healthy donor T cells with in vitro stimulatory (anti-CD3/anti-CD28) or non-stimulatory conditions. Flow cytometry was used to quantify T cell proliferation and expression of the checkpoint inhibitor molecules CTLA-4 and PD-1. Unexpectedly, we did not observe a direct lymphotoxic effect of dexamethasone on either unstimulated or stimulated healthy donor T cells during in vitro culture as measured by absolute cell numbers. However, dexamethasone induced a fourfold increase in the expression of the T cell inhibitory receptor CTLA-4 under stimulatory conditions. A similar change was not noted with unstimulated T cells. These findings identify a potential mechanism for corticosteroid treatment-induced immune suppression. CTLA-4 ligation, as occurs in vivo, provides a powerful inhibitory signal to T cells. CTLA-4 blockade may help to protect activated lymphocytes from the immune suppressive effects of corticosteroids. This could possibly explain how corticosteroids can reverse some checkpoint inhibitor toxicity without reducing efficacy. These results have important implications for the timing of corticosteroid use in patients with brain tumors undergoing checkpoint inhibitor treatment.
High-Density SNP Arrays Reveals the Possible Presence of Multi-Loci Genetic Predisposition for Myelodysplastic Syndromes (MDS).
Authors: Lukasz P. Gondek, Marcin W. Wlodarski, Zachary P. Nearman, Abdo Haddad, Ramon Tiu, Mikkael A. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2006)
Long-Term Immune Deficiency (ID) after Allogeneic Stem Cell Transplantation (allo-SCT) Following a Myeloablative (MA) Conditioning Regimen.
Authors: Elise Corre, Maryvonnick Carmagnat, Marc Busson, Regis Peffault de Latour, Marie Robin, Patricia Ribaud, Antoine Toubert, Claire Rabian, Gerard Socie
Journal: Blood (2008)
The Clinical Outcomes of Autologous Stem Cell Transplantation in Peripheral T Cell Lymphoma: from Retrospective Multicenter Study in Korea.
Authors: Deok-Hwan Yang, Won Seog Kim, Seok Jin Kim, Sung Hwa Bae, Sung Hyun Kim, In Ho Kim, Yeung-Chul Mun, Ho-Jin Shin, Yee Soo Chae, Jae-Yong Kwak, Hawk Kim, Min Kyoung Kim, Jin Seok Kim, Jin Ho Baek, Cheol Won Suh, Hee Sook Park16
Journal: Blood (2007)
RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks
Authors: Philipp C. Rommel, Thiago Y. Oliveira, Michel C. Nussenzweig, Davide F. Robbiani
Journal: The Journal of Experimental Medicine (2017)

The RAG recombinase (RAG1/2) plays an essential role in adaptive immunity by mediating V(D)J recombination in developing lymphocytes. In contrast, aberrant RAG1/2 activity promotes lymphocyte malignancies by causing chromosomal translocations and DNA deletions at cancer genes. RAG1/2 can also induce genomic DNA insertions by transposition and trans-V(D)J recombination, but only few such putative events have been documented in vivo. We used next-generation sequencing techniques to examine chromosomal rearrangements in primary murine B cells and discovered that RAG1/2 causes aberrant insertions by releasing cleaved antibody gene fragments that subsequently reintegrate into DNA breaks induced on a heterologous chromosome. We confirmed that RAG1/2 also mobilizes genomic DNA into independent physiological breaks by identifying similar insertions in human lymphoma and leukemia. Our findings reveal a novel RAG1/2-mediated insertion pathway distinct from DNA transposition and trans-V(D)J recombination that destabilizes the genome and shares features with reported oncogenic DNA insertions.